Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Cristina Muzi
Observed name:
C. Muzi
Institution:
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Observed institution:
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
ORCID:
0000-0002-6742-3222
Observed ORCID:
0000-0002-6742-3222
OpenAlex ID:
A5084970661
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
2022
·
Chiara Rusconi
, Chan Y. Cheah
, et al.
·
Blood
·
50
PDF
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients
2020
·
Domenico Albano
, Angelica Mazzoletti
, et al.
·
Annals of Hematology
·
44
Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience
2021
·
Vittorio Ruggero Zilioli
, Domenico Albano
, et al.
·
Journal of Cachexia Sarcopenia and Muscle
·
37
PDF
Comparison between skeletal muscle and adipose tissue measurements with high-dose CT and low-dose attenuation correction CT of 18F-FDG PET/CT in elderly Hodgkin lymphoma patients: a two-centre validation
2021
·
Domenico Albano
, Luca Camoni
, et al.
·
British Journal of Radiology
·
32
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study
2025
·
Carlo Visco
, Valentina Tabanelli
, et al.
·
The Lancet Haematology
·
9
PDF
Clinical and prognostic role of interim 18F-FDG PET/CT in elderly Hodgkin lymphoma: a dual-center experience
2020
·
Domenico Albano
, Angelica Mazzoletti
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
9
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE‐FIRST study
2025
·
Francesca Maria Quaglia
, Annalisa Arcari
, et al.
·
HemaSphere
·
3
PDF
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD
2025
·
Chiara Rusconi
, Angelica Barone
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
3
Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review
2023
·
Vittorio Ruggero Zilioli
, Cristina Muzi
, et al.
·
Cancers
·
3
PDF
Safety and Efficacy of Netupitant/Palonosetron and Dexamethasone in Classical Hodgkin’s Lymphoma Patients with Inadequate Chemotherapy-Induced Nausea and Vomiting Prophylaxis with Palonosetron and Dexamethasone: A Single-Center Real-Life Experience
2020
·
Vittorio R Zilioli
, Cristina Muzi
, et al.
·
International Journal of Hematologic Oncology
·
3
Ibrutinib Compared to Standard Chemotherapy for Central Nervous System Recurrence of Mantle Cell Lymphoma
2019
·
C. Rusconi
, D. Tucker
, et al.
·
Hematological Oncology
·
3
Prognostic Factors, Management and Outcome of an International Series of 41 Patients With Primary Mediastinal Large B‐cell Lymphoma (pmlbcl) and Central Nervous System (cns) Involvement
2021
·
A. J.M. Ferreri
, V. Tarantino
, et al.
·
Hematological Oncology
·
2
Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience
2024
·
Vittorio Ruggero Zilioli
, Emanuele Cencini
, et al.
·
Hematological Oncology
·
1
PDF
Rituximab and Lenalidomide (R 2) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)
2023
·
Carola Boccomini
, Barbara Botto
, et al.
·
Blood
·
1
Decisional Role of Interim PET in Relapsed/Refractory Classical Hodgkin Lymphoma Treated with Begev Chemotherapy As First Salvage
2022
·
Chiara Rusconi
, Francesca Ricci
, et al.
·
Blood
·
1
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial
2026
·
Riccardo Moia
, Mohammad Almasri
, et al.
·
Blood Advances
RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma
2026
·
Barbara Botto
, Carola Boccomini
, et al.
·
Blood Advances
Primary Cardiac Lymphoma: A Rare Case of Classical Hodgkin Lymphoma
2026
·
Cristina Muzi
, Vittorio Ruggero Zilioli
, et al.
·
Annals of Case Reports
PDF
Author response for "Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience"
2024
·
Vittorio Ruggero Zilioli
, Emanuele Cencini
, et al.
·
Publons reviews and discussion
Is Interim PET a Useful and Used Tool in Classical Hodgkin Lymphoma? Results from a Retrospective Multicenter Italian Experience
2023
·
Vittorio Ruggero Zilioli
, Emanuele Cencini
, et al.
·
Blood
P1070: Decisional Role of Interim Pet in Relapsed/refractory Classical Hodgkin Lymphoma Treated With Begev Chemotherapy as First Salvage
2023
·
Chiara Rusconi
, Francesca Ricci
, et al.
·
HemaSphere
P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
2022
·
Chiara Rusconi
, Francesca Ricci
, et al.
·
HemaSphere
Sarcopenia Is an Independent Prognostic Factor in Elderly Male Patients With Classical Hodgkin Lymphoma: Results From a Multicenter Experience
2021
·
V. R. Zilioli
, D. Albano
, et al.
·
Hematological Oncology
PDF
Un caso di linfoma surrenalico bilaterale
2020
·
Emilia Biamonte
, Erika Maria Grossrubatscher
, et al.
·
L Endocrinologo
Show more works
View as search
Works count:
26
Citation count:
201
H-index:
6
I10-index:
4
Year
Topic
Type